Export Compliance Daily is a service of Warren Communications News.
Subscriber Login
“AbbVie” articles
to
articlessource documents
Refine Search

Search Primer

Term list: Separate terms with spaces, not commas or semicolons.

Multi-word term: Place inside quotes to ensure an exact match (e.g. "China import").

Acronyms: Use all capital letters to ensure the search is not looking for that letter sequence instead.

Required term: If a term must be included in any resulting articles, prefix it with a plus sign (e.g., +CBP).

Excluded term: If a term should be excluded from any articles being found, prefix it with a minus sign (e.g., -ruling).

Singular form: Always use the singular form when doing multi-word terms (e.g. "russian export control" instead of "russian export controls").

Shortest word form: When you have different word forms in a quoted (multi-word) term, you want to only include the shortest version if it is the last part of the expression (e.g., "entity list" instead of "entity listing" or "entity listed").

ITC Begins Section 337 Investigation on Antirheumatic Drug
January 28, 2022 by Ben Perkins|AD/CV - Patent

The International Trade Commission officially opened an investigation into alleged misappropriation of trade secrets relating to the manufacture of the antirheumatic drug Adalimumab. The investigation (ITC Inv. No. 337-TA-1296) is based on a complaint filed by AbbVie Dec. 17 (see 2112230048), alleging that Alvotech, Teva Pharmaceutical Industries and Ivers-Lee engaged in "a scheme to improperly recruit employees with knowledge of AbbVie's manufacturing process for Adalimumab," in an attempt to market a biosimilar called AVT02. AbbVie asked the ITC to issue a limited exclusion order and cease and desist orders banning importation and sale of covered goods by Alvotech, Teva and Ivers-Lee and their affiliates.

AbbVie Seeks Section 337 Import Ban on Humira Biosimilar
December 23, 2021 |AD/CV - Patent

AbbVie seeks a ban on imports of adalimumab biosimilars from Alvotech, Teva and Ivers-Lee that allegedly rely on misappropriated trade secrets, it told the International Trade Commission in a Section 337 compaint filed Dec. 17. AbbVie says the companies seek to bring to market a biologic called AVT02, which is similar to AbbVie’s Humira brand adalimumab, used to treat a variety of conditions such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis. AbbVie seeks a limited exclusion order and cease and desist orders against AlvoTech, Teva and Ivers-Lee. Comments are due to the ITC Jan. 3.